Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:PTGX
- CUSIP: N/A
- Web: www.protagonist-inc.com
- Market Cap: $284.8 million
- Outstanding Shares: 16,902,000
- 50 Day Moving Avg: $13.69
- 200 Day Moving Avg: $12.13
- 52 Week Range: $8.00 - $26.36
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.46
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $3.61 per share
- Price / Book: 4.67
- EBIDTA: ($47,600,000.00)
- Return on Equity: -59.45%
- Return on Assets: -54.53%
- Current Ratio: 7.38%
- Quick Ratio: 7.38%
- Average Volume: 76,142 shs.
- Short Ratio: 9.47
Frequently Asked Questions for Protagonist Therapeutics (NASDAQ:PTGX)
What is Protagonist Therapeutics' stock symbol?
Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."
How were Protagonist Therapeutics' earnings last quarter?
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.70. View Protagonist Therapeutics' Earnings History.
When will Protagonist Therapeutics make its next earnings announcement?
Where is Protagonist Therapeutics' stock going? Where will Protagonist Therapeutics' stock price be in 2017?
2 brokers have issued 12 month target prices for Protagonist Therapeutics' shares. Their forecasts range from $36.00 to $45.00. On average, they expect Protagonist Therapeutics' share price to reach $40.50 in the next twelve months. View Analyst Ratings for Protagonist Therapeutics.
Who are some of Protagonist Therapeutics' key competitors?
Some companies that are related to Protagonist Therapeutics include Inovio Pharmaceuticals (INO), Celyad SA (CYAD), Kala Pharmaceuticals (KALA), PDL BioPharma (PDLI), Adamas Pharmaceuticals (ADMS), Voyager Therapeutics (VYGR), Mesoblast Limited (MESO), Cara Therapeutics (CARA), Agenus (AGEN), Arbutus Biopharma Corporation (ABUS), Celldex Therapeutics (CLDX), Corvus Pharmaceuticals (CRVS), Novavax (NVAX), Idera Pharmaceuticals (IDRA), NewLink Genetics Corporation (NLNK), Concert Pharmaceuticals (CNCE), Puretech Health PLC (PRTC) and Codexis (CDXS).
Who are Protagonist Therapeutics' key executives?
Protagonist Therapeutics' management team includes the folowing people:
- Harold E. Selick Ph.D., Independent Chairman of the Board
- Dinesh V. Patel Ph.D., President, Chief Executive Officer, Director
- Thomas P. O'Neil, Chief Financial Officer
- William A. Hodder, Senior Vice President - Corporate Development
- David Y. Liu Ph.D., Chief Scientific Officer, Head of Research & Development
- Ashok Bhandari Ph.D., Vice President - Chemistry
- Larry Mattheakis Ph.D., Vice President - Biology
- Mark Smythe Ph.D., Vice President -Technology & Alliances
- Thamil Annamalai, Senior Director - Pre-clinical Development
- Richard S. Shames M.D., Chief Medical Officer
When did Protagonist Therapeutics IPO?
(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.
Who owns Protagonist Therapeutics stock?
Protagonist Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Pharmstandard International S.A. (5.81%), Vanguard Group Inc. (1.93%), Senzar Asset Management LLC (1.62%), State Street Corp (0.67%) and Northern Trust Corp (0.59%). Company insiders that own Protagonist Therapeutics stock include Armen Shanafelt, David Y Liu and Richard S Shames. View Institutional Ownership Trends for Protagonist Therapeutics.
Who sold Protagonist Therapeutics stock? Who is selling Protagonist Therapeutics stock?
Protagonist Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including PDT Partners LLC. Company insiders that have sold Protagonist Therapeutics stock in the last year include David Y Liu and Richard S Shames. View Insider Buying and Selling for Protagonist Therapeutics.
Who bought Protagonist Therapeutics stock? Who is buying Protagonist Therapeutics stock?
Protagonist Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, State Street Corp, Northern Trust Corp, Northern Capital Management LLC, Vanguard Group Inc., FMR LLC, Rhumbline Advisers and Teachers Advisors LLC. View Insider Buying and Selling for Protagonist Therapeutics.
How do I buy Protagonist Therapeutics stock?
Shares of Protagonist Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protagonist Therapeutics' stock price today?
MarketBeat Community Rating for Protagonist Therapeutics (NASDAQ PTGX)MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Protagonist Therapeutics stock can currently be purchased for approximately $16.85.
Earnings History for Protagonist Therapeutics (NASDAQ:PTGX)Earnings History by Quarter for Protagonist Therapeutics (NASDAQ PTGX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Protagonist Therapeutics (NASDAQ:PTGX)
2017 EPS Consensus Estimate: ($3.50)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Protagonist Therapeutics (NASDAQ:PTGX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Protagonist Therapeutics (NASDAQ:PTGX)
Institutional Ownership Percentage: 48.04%Insider Trades by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/12/2017||Richard S. Shames||Insider||Sell||3,687||$14.31||$52,760.97|| |
|8/29/2017||Richard S. Shames||Insider||Sell||1,512||$17.00||$25,704.00|| |
|8/28/2017||David Y Liu||Insider||Sell||3,500||$15.00||$52,500.00|| |
|7/10/2017||David Y. Liu||Insider||Sell||3,500||$12.68||$44,380.00|| |
|8/16/2016||Armen Shanafelt||Director||Buy||583,333||$12.00||$6,999,996.00|| |
Headline Trends for Protagonist Therapeutics (NASDAQ:PTGX)
Latest Headlines for Protagonist Therapeutics (NASDAQ:PTGX)
|Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300|
finance.yahoo.com - September 22 at 2:39 PM
|Analysts Issue Forecasts for Protagonist Therapeutics, Inc.'s FY2019 Earnings (PTGX)|
www.americanbankingnews.com - September 22 at 12:52 PM
|/C O R R E C T I O N -- Protagonist Therapeutics, Inc./|
finance.yahoo.com - September 15 at 7:51 AM
|Protagonist Therapeutics, Inc. (PTGX) Insider Richard S. Shames Sells 3,687 Shares|
www.americanbankingnews.com - September 12 at 10:16 PM
|Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference|
finance.yahoo.com - September 12 at 8:50 AM
|Protagonist Therapeutics, Inc. (PTGX) Rating Lowered to Sell at ValuEngine|
www.americanbankingnews.com - September 11 at 10:18 PM
|Protagonist Therapeutics (PTGX) and Jaguar Animal Health (JAGX) Critical Comparison|
www.americanbankingnews.com - September 1 at 6:06 AM
|Insider Selling: Protagonist Therapeutics, Inc. (PTGX) Insider Sells 1,512 Shares of Stock|
www.americanbankingnews.com - August 30 at 8:50 PM
|Protagonist Therapeutics, Inc. (PTGX) Insider David Y. Liu Sells 3,500 Shares|
www.americanbankingnews.com - August 29 at 10:34 PM
|Protagonist Therapeutics, Inc. (PTGX) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - August 29 at 12:40 AM
|Protagonist Therapeutics, Inc. (PTGX) Raised to "Hold" at ValuEngine|
www.americanbankingnews.com - August 28 at 11:14 PM
|Protagonist Therapeutics (PTGX) Announces Closing of Janssen Pact for PTG-200 and Receipt of $50M Payment|
www.streetinsider.com - August 25 at 10:23 AM
|Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment|
finance.yahoo.com - August 25 at 10:23 AM
|Zacks: Brokerages Set $29.67 Price Target for Protagonist Therapeutics, Inc. (PTGX)|
www.americanbankingnews.com - August 25 at 2:26 AM
|Zacks: Brokerages Set $29.67 Target Price for Protagonist Therapeutics, Inc. (PTGX)|
www.americanbankingnews.com - August 21 at 8:08 PM
|Protagonist Therapeutics, Inc. (PTGX) Expected to Post Earnings of -$0.95 Per Share|
www.americanbankingnews.com - August 18 at 6:12 PM
|Zacks Investment Research Upgrades Protagonist Therapeutics, Inc. (PTGX) to Buy|
www.americanbankingnews.com - August 18 at 6:56 AM
|Leerink Swann Research Analysts Raise Earnings Estimates for Protagonist Therapeutics, Inc. (PTGX)|
www.americanbankingnews.com - August 17 at 8:04 AM
|Zacks: Protagonist Therapeutics, Inc. (PTGX) Given $29.67 Average Price Target by Brokerages|
www.americanbankingnews.com - August 14 at 6:16 AM
|Protagonist Therapeutics, Inc. (PTGX) Issues Quarterly Earnings Results, Misses Estimates By $0.70 EPS|
www.americanbankingnews.com - August 9 at 4:46 PM
|Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights|
finance.yahoo.com - August 9 at 6:40 AM
|Brokerages Expect Protagonist Therapeutics, Inc. (PTGX) to Announce ($0.92) Earnings Per Share|
www.americanbankingnews.com - July 30 at 10:04 PM
|Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Coverage Initiated by Analysts at BTIG Research|
www.americanbankingnews.com - July 22 at 7:03 PM
|David Y. Liu Sells 3,500 Shares of Protagonist Therapeutics, Inc. (PTGX) Stock|
www.americanbankingnews.com - July 12 at 8:42 PM
|Brokerages Expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to Announce ($0.92) EPS|
www.americanbankingnews.com - July 12 at 4:18 PM
|-$0.92 Earnings Per Share Expected for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) This Quarter|
www.americanbankingnews.com - July 7 at 10:53 AM
| Protagonist Therapeutics, Inc. (PTGX) Given Consensus Rating of "Strong Buy" by Analysts|
www.americanbankingnews.com - June 21 at 7:50 AM
|Protagonist Therapeutics, Inc. (PTGX) Expected to Announce Earnings of -$0.92 Per Share|
www.americanbankingnews.com - June 13 at 10:20 AM
|Protagonist Therapeutics, Inc. (PTGX) Sees Large Increase in Short Interest|
www.americanbankingnews.com - June 12 at 7:12 AM
|Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors|
finance.yahoo.com - June 8 at 8:59 AM
|A small biotech wants to disrupt billion-dollar injectable drug markets with a single pill|
finance.yahoo.com - June 7 at 7:18 PM
|FY2018 EPS Estimates for Protagonist Therapeutics Inc (PTGX) Decreased by Analyst|
www.americanbankingnews.com - June 5 at 7:37 AM
|Protagonist Therapeutics Inc. (PTGX) Jumped On Janssen Biotech Deal|
www.rttnews.com - May 31 at 1:01 PM
|Why Analysts Think Protagonist Therapeutics Could Still More Than Double After the News|
finance.yahoo.com - May 31 at 1:01 PM
|Protagonist Therapeutics Inc (PTGX) Stock Rating Reaffirmed by BMO Capital Markets|
www.americanbankingnews.com - May 31 at 8:40 AM
|Can Protagonist Therapeutics Stock Still Double After Its Huge Gain?|
247wallst.com - May 30 at 7:03 PM
|Protagonist Therapeutics Inc. (PTGX) Is Up Sharply On Collaboration Agreement|
www.nasdaq.com - May 30 at 7:03 PM
|Protagonist Therapeutics Inks License Pact With Johnson & Johnson's Janssen|
finance.yahoo.com - May 30 at 7:03 PM
|Protagonist Therapeutics Spikes Sharply After Agreement With Janssen|
feeds.benzinga.com - May 30 at 11:43 AM
|Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease|
finance.yahoo.com - May 30 at 9:43 AM
|Why Protagonist Therapeutics Shares Are Climbing|
finance.yahoo.com - May 30 at 9:43 AM
|Zacks: Protagonist Therapeutics Inc (PTGX) Receives Average Rating of "Strong Buy" from Analysts|
www.americanbankingnews.com - May 29 at 12:30 PM
|Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300|
finance.yahoo.com - May 26 at 6:12 AM
|Protagonist Therapeutics (PTGX) Awarded $1.34M in SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist|
www.streetinsider.com - May 25 at 12:40 AM
|Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity|
finance.yahoo.com - May 24 at 9:57 AM
|Leerink Swann Brokers Lower Earnings Estimates for Protagonist Therapeutics Inc (PTGX)|
www.americanbankingnews.com - May 17 at 7:46 AM
|Zacks: Brokerages Anticipate Protagonist Therapeutics Inc (PTGX) Will Announce Earnings of -$0.66 Per Share|
www.americanbankingnews.com - May 16 at 6:24 PM
|Protagonist Therapeutics Inc (PTGX) Issues Earnings Results|
www.americanbankingnews.com - May 11 at 6:14 PM
|Protagonist Therapeutics Reports First Quarter 2017 Financial Results|
finance.yahoo.com - May 10 at 7:34 PM
|Protagonist Therapeutics posts 1Q loss|
finance.yahoo.com - May 10 at 7:34 PM
Protagonist Therapeutics (PTGX) Chart for Sunday, September, 24, 2017